Emcure Pharmaceuticals Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 36% at ₹3.6/Share	04-Sep-2026	04-Sep-2026
DividendsFinal Dividend of 30% at ₹3/Share	14-Aug-2025	14-Aug-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Aditya Birla Sun Life ELSS Tax Saver Fund - IDCW	13.50 Lac	13.50 Lac no change
HSBC Small Cap Fund - Regular Plan - Growth	8.85 Lac	8.85 Lac no change
Aditya Birla Sun Life Multi-Cap Fund - Regular Plan - Growth	4.40 Lac	4.40 Lac no change
Aditya Birla Sun Life Small Cap Fund - Growth	3.94 Lac	3.94 Lac no change
Aditya Birla Sun Life Large & Mid Cap Fund - Regular Plan - IDCW	2.76 Lac	2.76 Lac no change

DHARMESH BHATT R A

2 Oct • 10:04 PM · SEBI-Registered Analyst

Emcure Pharmaceuticals : Penalty Orders ₹57.74 Crore

DHARMESH BHATT (Research Analyst) SEBI Registration No. INH000009685

EMCURE

Emcure Pharmaceuticals Limited has informed stock exchanges (NSE: EMCURE / BSE: 544210) regarding regulatory orders received from the Income Tax Department. The disclosures, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outline an aggregate penalty exceeding ₹57.73 crore spanning seven financial years. Key HighlightsTotal Financial Impact: Aggregate penalty imposed stands at ₹57,73,96,732. Applicable Assessment Period: Financial Years 2014-15 to 2020-21 (Assessment Years 2015-16 to 2021-22). Adjudicating Authority: Deputy Commissioner of Income Tax, Central Circle 2(1) – Pune. Dispute Timeline: Litigation originally initiated on December 27, 2023. Company Response: Emcure is evaluating legal remedies and intends to file an appeal before the Appellate Authority.

Palak Jain

3 Sep • 10:07 AM · SEBI-Registered Analyst

Rs 229 dividend payout, stock split, bonus issue:

Ex-Date Stocks, September 4: AIA Engineering, Coal India, Emcure Pharmaceuticals, Finolex Cables, Oil India and ONGC, among others, turn ex-date on September 4 for dividends and corporate actionsEx-Date Stocks, September 4: Investors looking to qualify for dividends and other corporate actions may consider buying eligible stocks on Thursday, September 3, as several companies are set to turn ex-date on Friday, September 4. Collectively, the companies listed have announced dividend payouts of Rs 228.53 per share, based on the individual payouts provided. Federal-Mogul Goetze (India) has the highest payout at Rs 94 per share (Rs 7.50 interim + Rs 86.50 special), while Fineotex Chemical has the lowest at Rs 0.05 per share. Under the T+1 settlement cycle, investors generally need to buy the shares one trading day before the ex-date to be eligible for the announced dividend.

IOC

Ankush

13 Aug • 12:29 PM · SEBI-Registered Analyst

India Pharma Market Grows 12.1% in July, Led by Zydus Lifesciences and Sun Pharma

SUNPHARMA

India’s pharmaceutical market grew 12.1% year-on-year in July 2026, marking a strong recovery after subdued growth. According to Analyst latest note, the market has maintained double-digit growth, supported by price increases, new product launches and improving volumes. Sales growth in July was driven by a 6% increase in prices. The recovery was supported by a favourable low volume base, higher contributions from new launches such as GLP-1 drugs, and stronger demand across chronic therapies, including cardiac and neurological treatments, as well as VMNs and oncology. Zydus Lifesciences and Sun Pharma recorded the strongest year-on-year growth in July in value terms. On a moving annual total basis, Torrent Pharma led growth at 14.4%, followed by Glenmark and Zydus Lifesciences at 14.2% each. Among major therapy segments, anti-diabetes recorded the fastest growth in July, followed by vitamins, minerals and nutrients (VMNs). Anti-diabetes growth was largely driven by new product launches, with GLP-1 therapies accounting for around 48% of the segment’s growth. VMN growth, meanwhile, was primarily price-led. Cardiac, respiratory, pain, neurology and gynaecology therapies also posted double-digit growth. In contrast, gastro, anti-infectives and dermatology witnessed muted single-digit growth, mainly due to weak volume growth, according to Pharmarack data. At the company level, IPCA Laboratories benefited from strong double-digit growth in pain and cardiology, although weakness in anti-malaria and anti-infective products weighed on overall performance. Growth was relatively subdued for Mankind Pharma, Emcure.

Prachi Mehta

10 Aug • 6:47 PM · SEBI-Registered Analyst

Update for investors of

Emcure

Pharma

EMCURE

is currently trading at Rs. 1987.10, up by 10.00 points or 0.51% from its previous closing of Rs. 1977.10 on the BSE. The scrip opened at Rs. 2007.65 and has touched a high and low of Rs. 2047.40 and Rs. 1,980.15 respectively. So far 5703 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2,047.40 on 10-Aug-2026 and a 52 week low of Rs. 1260.10 on 30-Sep-2025. Last one week high and low of the scrip stood at Rs. 2,047.40 and Rs. 1911.15 respectively. The current market cap of the company is Rs. 37822.22 crore. The promoters holding in the company stood at 77.83%, while Institutions and Non-Institutions held 13.34% and 8.83% respectively. Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat. The USFDA conducted this inspection from May 06, 2026 to May 15, 2026. The USFDA has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed. Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Pavan Rawat

10 Aug • 1:59 PM · SEBI-Registered Analyst

Emcure Pharmaceuticals Shares in Focus After USFDA Inspection Closure

EMCURE

Emcure Pharmaceuticals shares are likely to remain in focus on August 10 after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations facility in Sanand, Gujarat. The EIR follows an inspection conducted between May 6 and May 15, 2026, with the USFDA classifying the inspection as Voluntary Action Indicated (VAI). The inspection has now been closed. Analysts have raised their earnings estimates for Emcure Pharmaceuticals, citing strong growth in its antiretroviral (ARV) order book in rest-of-world markets, continued expansion of its European business and increasing efforts in the domestic formulations segment. The positive outlook reflects expectations of sustained business growth across key markets. For the June quarter, Emcure Pharmaceuticals reported a 36.2% year-on-year increase in consolidated net profit to ₹292 crore, while revenue from operations rose 22.8% to ₹2,580 crore. EBITDA increased 25.8%, with the margin improving to 19.7%. Shares closed at ₹1,977.10 in the previous session, up 2.12%, and are trading close to their 52-week high.

Pradeep Carpenter

10 Aug • 8:44 AM · SEBI-Registered Analyst

Indian Market Insights – 10 August 2026

Indian equity markets are expected to remain in a consolidation phase with a neutral bias on the daily charts, while healthy sector rotation continues to support the broader market structure. The overall trend remains constructive, and a buy-on-dips approach can be considered as long as key support levels are protected. On the technical front, Nifty has strong intraday support in the 24,400–24,420 zone. Holding this area can keep the index positive and support a move towards 24,700–24,750, which remains the key resistance zone. A sustained breakout above this range could improve momentum further. Bank Nifty has also remained range-bound over the past few sessions and is likely to continue consolidating in today’s trade. Key support is placed around 57,100–57,250, while immediate resistance is seen at 58,200–58,250, followed by 58,500. From the derivatives perspective, FIIs created fresh short positions during Friday’s session, so today’s closing price action will be important. Traders should closely monitor whether these shorts continue to build or start getting covered, as this could influence the next directional move. Key Cues for Today Positive: Strong U.S. jobs data could support global risk sentiment. Negative: Rising crude oil prices remain a concern, particularly for oil-importing economies like India, as higher crude can impact inflation and corporate margins. Stocks to Watch

TITAN

, Oil India, Signature Global, Emcure Pharma, RITES, Anaview Wire, Anant Raj, Nitin Spinners, Akums Drugs and Ambika Cotton will remain in focus today. Overall Strategy: Keep a positive bias above key supports, prefer buying on dips, and avoid aggressive positions while Nifty and Bank Nifty remain within their current ranges.

Emcure Pharmaceuticals Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Emcure Pharmaceuticals Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Emcure Pharmaceuticals Ltd.?

What is the market cap of Emcure Pharmaceuticals Ltd.?

Should I buy Emcure Pharmaceuticals Ltd. stock now?

What is the 52 week high and low of Emcure Pharmaceuticals Ltd.?

Is the Emcure Pharmaceuticals Ltd. stock good to buy?

Is Emcure Pharmaceuticals Ltd. a good buy for the long term?

Is Emcure Pharmaceuticals Ltd. overvalued or undervalued?

What is the PE and PB ratio of Emcure Pharmaceuticals Ltd.?